Europe ready to cash in on cheap copies of AbbVie biotech drug

LONDON/NEW YORK (Reuters) - U.S. drugmaker AbbVie ABBV.N faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – hit the market.With vast sums at stake, European healthcare administrators say they will waste no time in exploiting the situation to drive down drug bills."The opportunity is too big miss," said Jatinder Harchowal, one of the coordinators of Britain's push for..